FCS Associates

Life Sciences Innovative Manufacturing Fund

The LSIMF will provide £60 million in capital grants for investment in the manufacture of:

  • human medicines (drug substance and drug product)
  • medical diagnostics
  • MedTech products

We will prioritise applicants based on their alignment to the fund’s objectives:

  1. Creating economic opportunity through investments that will provide high-wage, high-skilled jobs.
  2. Deploying cutting-edge innovations (at both pilot and commercial scale) which can be embedded in either the product itself or the manufacturing process.
  3. Increasing health resilience, either through increased domestic capacity or by providing flexible capabilities that can be re-deployed in some way in a future health emergency.
  4. Minimising impact on the environment, which might include reduction in input resources or using alternative input materials to become more sustainable or support the government’s net zero target.

We particularly encourage applications from companies ready to deploy their emerging technologies at scale in commercial manufacturing.

The fund will be in 2 phases (March to May 2022 and September to November 2022), with monthly deadlines to submit EOIs.

Phase 1 closing dates:

  • Wave 1: Thursday 31 March 2022, 12pm (noon)
  • Wave 2: Friday 29 April 2022, 12pm (noon)
  • Wave 3: Tuesday 31 May 2022, 12pm (noon)

Click here to find out more. 

Location: UK

Value: various

Deadline: EOIs 31 May 2022

Date Added: 24 Mar 2022

Our success rate

Need help applying for this grant?

Yes, Please help me write a winning applicationNo, just keep me up-to-date with the latest grants
Twitter Twitter Feed @FCSAssociates
  • RT @Veitchie: I'll be honest, take up for our Fearless Finances workshop is low. I get it, we avoid ££ because delivery is so important, es…
Twitter LinkedIn YouTube
Life Sciences Innovative Manufacturing Fund - FCS Associates

Life Sciences Innovative Manufacturing Fund

The LSIMF will provide £60 million in capital grants for investment in the manufacture of:

  • human medicines (drug substance and drug product)
  • medical diagnostics
  • MedTech products

We will prioritise applicants based on their alignment to the fund’s objectives:

  1. Creating economic opportunity through investments that will provide high-wage, high-skilled jobs.
  2. Deploying cutting-edge innovations (at both pilot and commercial scale) which can be embedded in either the product itself or the manufacturing process.
  3. Increasing health resilience, either through increased domestic capacity or by providing flexible capabilities that can be re-deployed in some way in a future health emergency.
  4. Minimising impact on the environment, which might include reduction in input resources or using alternative input materials to become more sustainable or support the government’s net zero target.

We particularly encourage applications from companies ready to deploy their emerging technologies at scale in commercial manufacturing.

The fund will be in 2 phases (March to May 2022 and September to November 2022), with monthly deadlines to submit EOIs.

Phase 1 closing dates:

  • Wave 1: Thursday 31 March 2022, 12pm (noon)
  • Wave 2: Friday 29 April 2022, 12pm (noon)
  • Wave 3: Tuesday 31 May 2022, 12pm (noon)

Click here to find out more. 

Location: UK

Value: various

Deadline: EOIs 31 May 2022

Date Added: 24 Mar 2022

Our success rate

Need help applying for this grant?

Yes, Please help me write a winning applicationNo, just keep me up-to-date with the latest grants
Life Sciences Innovative Manufacturing Fund - FCS Associates

Life Sciences Innovative Manufacturing Fund

The LSIMF will provide £60 million in capital grants for investment in the manufacture of:

  • human medicines (drug substance and drug product)
  • medical diagnostics
  • MedTech products

We will prioritise applicants based on their alignment to the fund’s objectives:

  1. Creating economic opportunity through investments that will provide high-wage, high-skilled jobs.
  2. Deploying cutting-edge innovations (at both pilot and commercial scale) which can be embedded in either the product itself or the manufacturing process.
  3. Increasing health resilience, either through increased domestic capacity or by providing flexible capabilities that can be re-deployed in some way in a future health emergency.
  4. Minimising impact on the environment, which might include reduction in input resources or using alternative input materials to become more sustainable or support the government’s net zero target.

We particularly encourage applications from companies ready to deploy their emerging technologies at scale in commercial manufacturing.

The fund will be in 2 phases (March to May 2022 and September to November 2022), with monthly deadlines to submit EOIs.

Phase 1 closing dates:

  • Wave 1: Thursday 31 March 2022, 12pm (noon)
  • Wave 2: Friday 29 April 2022, 12pm (noon)
  • Wave 3: Tuesday 31 May 2022, 12pm (noon)

Click here to find out more. 

Location: UK

Value: various

Deadline: EOIs 31 May 2022

Date Added: 24 Mar 2022

Our success rate

Need help applying for this grant?

Yes, Please help me write a winning applicationNo, just keep me up-to-date with the latest grants